PharmiWeb.com - Global Pharma News & Resources
10-Jul-2019

NET Treatment Market Size to Cross USD 4.2 Billion by 2026

The global NET Treatment Market Size projected to register USD 4.2 billion by 2026, registering at a CAGR growth of 10.1% over the forecast period 2018 to 2026.Growing extensiveness of characinoid tumors is anticipated to drive the NET treatment market during the forthcoming years. Huge investment in clinical trials by numerous pharmaceutical businesses to develop new products is another parameters driving the NET treatment market development.

Such as, Novartis AG has the witnessed highest numeral of clinical trials followed by the company named Pfizer Inc. and Ipsen Pharma. Furthermore, technical advancements in therapies to treat neuroendocrine tumors are expected to drive the NET treatment market development over the coming years. Few of these comprise of targeted drug therapies, PET imaging with Ga labeled Somatostatin, and tyrosine kinase therapies. Such as, Lutathera by Novartis AG received FDA sanction for the first ever radio nucleotide therapy.

Many of these businesses have undertaken policies, for instance, product launch, regional development, strategic partnership and distribution agreements, to reinforce their market position. Such as, Novartis AG declared to purchase all the ordinary shares from its subsidiary group Novartis Groupe France S.A. in January 2018.

Boehringer Ingelheim publicised to invest around USD 270 million to develop(BDC) new Biologicals Development Center focussed for immunology and immune-oncology in June 2018. The initiatives like these are anticipated to drive the NET treatment market growth over the forecast period.

Download Free Sample Report at https://www.acumenresearchandconsulting.com/request-sample/983

The global NET treatment market is segmented into product, site, end-user and region. On the basis of product, the global NET treatment market is segmented into somatostatin analogs (SSAs), targeted therapy, and others. On the basis of site, the global NET treatment market is segmented into lungs, pancreas, colon, small intestine, and others. On the basis of the end-user, the global NET treatment market is segmented into hospitals, clinics, and others. On the basis of region the global NET treatment market is segmented into Latin America, Europe, Asia Pacific, North America, and Middle East amp; Africa.

Based on end-user, Hospital sub-segment was the dominant of revenue share for global NET treatment market. The occurrence of developed technologies and obtainability of multiple options for NET diagnosis are anticipated to additionally increase the NET treatment segment growth.

Based on end-user, Clinics sub- segment is predictable to observe lucrative growth in the coming years owing to obtain ability of patient-centric treatment options and skilled surgeons. The others segment comprise of cancer research companies and government institutes and is expected to deliver high development potential for the market in the forthcoming years.

Europe captured the market share of more than 20.5% of the global market share during the forecast period. Greater extent of public funding in Europersquo;s healthcare system has backed to this development. Furthermore, occurrence of target populace base paired with government support to control cancer captures to significant development of this region. Such as, formation of bodies, for instance, the European Cancer Observatory, produced consciousness about cancer.

View Detail Report With Complete TOC at https://www.acumenresearchandconsulting.com/net-treatment-market

Asia Pacific is anticipated to observe the profitable development forthcoming due to helpful government initiatives and improving healthcare infrastructure. Furthermore, economic growths in countries, for instance, China and India, are anticipated to aid drive the market development. Enormous populace base with low per capita income in the region captures to high need for reasonable treatment options. North America captures the major market share in 2018 accounting for more than 35.6% of its share and is projected to continue its dominance during the forthcoming. Main parameter contributing to development of this region comprise government support for high purchasing power parity, quality healthcare, availability of reimbursement, and growing occurrence of cancers in Canada and U.S. Such as, in U.S., the (PPACA) Patient Protection and Affordable Care Act, also called as ObamaCare, encourages quality and affordability of health insurance and decreases the cost of healthcare for individuals and government. Government initiatives, for instance, Precision Medicine Initiative formulating tailored tactics on unique features of diseases, are aiding in improving the overall healthcare system, therefore increasing market development.

The key players catering to the global NET treatment market are Boehringer Ingelheim International GmbH, AVEO Oncology, Hutchison MediPharma Limited, Novartis AG, Ipsen Pharma,Pfizer, Inc., and Progenics Pharmaceuticals.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of NET Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. NET Treatment Market By Product
1.2.2.1. Global NET Treatment Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.2.2. Global NET Treatment Market Revenue Share By Product in 2017
1.2.2.3. Somatostatin Analogs (SSAs)
1.2.2.4. Targeted Therapy
1.2.2.5. Others
1.2.3. NET Treatment Market By Site
1.2.3.1. Global NET Treatment Market Revenue and Growth Rate Comparison By Site (2015-2026)
1.2.3.2. Lungs
1.2.3.3. Pancreas
1.2.3.4. Colon
1.2.3.5. Small Intestine
1.2.3.6. Others
1.2.4. NET Treatment Market By End Users
1.2.4.1. Global NET Treatment Market Revenue and Growth Rate Comparison By End Users (2015-2026)
1.2.4.2. Hospitals
1.2.4.3. Clinics
1.2.4.4. Others
1.2.5. NET Treatment Market by Geography
1.2.5.1. Global NET Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America NET Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe NET Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific NET Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America NET Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) NET Treatment Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global NET Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global NET Treatment Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global NET Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global NET Treatment Major Manufacturers in 2017

CHAPTER 4. NET TREATMENT MARKET BY PRODUCT

4.1. Global NET Treatment Revenue By Product
4.2. Somatostatin Analogs (SSAs)
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Targeted Therapy
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. NET TREATMENT MARKET BY SITE

5.1. Global NET Treatment Revenue By Site
5.2. Lungs
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Pancreas
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Colon
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Small Intestine
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Others
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NET TREATMENT MARKET BY END USERS

6.1. Global NET Treatment Revenue By End Users
6.2. Hospitals
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Clinics
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Others
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA NET TREATMENT MARKET BY COUNTRY

7.1. North America NET Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America NET Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. NET Treatment Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE NET TREATMENT MARKET BY COUNTRY

8.1. Europe NET Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe NET Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC NET TREATMENT MARKET BY COUNTRY

9.1. Asia-Pacific NET Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific NET Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA NET TREATMENT MARKET BY COUNTRY

10.1. Latin America NET Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America NET Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST NET TREATMENT MARKET BY COUNTRY

11.1. Middle East NET Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East NET Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA NET TREATMENT MARKET BY COUNTRY

12.1. Africa NET Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa NET Treatment Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Site, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By End Users, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. BoehringerIngelheim International GmbH
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. AVEO Oncology
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Hutchison MediPharma Limited
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Novartis AG
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. IpsenPharma
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Pfizer, Inc.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Progenics Pharmaceuticals
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Others
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

INQUIRY BEFORE BUYING: https://www.acumenresearchandconsulting.com/inquiry-before-buying/983

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report at https://www.acumenresearchandconsulting.com/buy-now/0/983

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 10-Jul-2019